Page 24 - 南京医科大学自然版

第46卷第6期
·806 · 南 京 医 科 大 学 学 报 2026年6月

primary［J］. Medicine，2020，99（50）：e23210 evaluation of radiotherapy［J］. Cancer Radiother，2020，24
［8］ WATANABE A，HARIMOTO N，YOKOBORI T，et al. （5）：388-397
FDG ⁃ PET reflects tumor viability on SUV in colorectal ［19］BIJLSTRA O D，BOREEL M M E，VAN MOSSEL S，et al.
cancer liver metastasis［J］. Int J Clin Oncol，2020，25（2）： The value of F⁃FDG⁃PET⁃CT imaging in treatment evalu⁃
18
322-329 ation of colorectal liver metastases：a systematic review［J］.
［9］ QIAO Y，LI X M，HU Y Q，et al. Relationship between Diagnostics，2022，12（3）：715
18
SUVmax on F⁃FDG PET and PD⁃L1 expression in liver ［20］JIN L，HU W Y，LI T，et al. Case report and literature re⁃
metastasis lesions after colon radical operation［J］. BMC view：PET/CT in the evaluation of response to treatment of
Cancer，2023，23（1）：535 liver metastasis from colorectal cancer with DEBIRI ⁃
［10］AKHURST T，GÖNEN M，BASER R E，et al. Prospective TACE［J］. Front Oncol，2023，13：1015976
18
evaluation of F ⁃ FDG positron emission tomography in ［21］LEE H S，KWON H W，LIM S B，et al. FDG metabolic pa⁃
the preoperative staging of patients with hepatic colorec⁃ rameter⁃based models for predicting recurrence after up⁃
tal metastases［J］. Hepatobiliary Surg Nutr，2022，11（4）： front surgery in synchronous colorectal cancer liver metas⁃
539-554 tasis［J］. Eur Radiol，2023，33（3）：1746-1756
［11］JONSSON J，HEMMINGSSON O，STRENGBOM R，et al. ［22］MAAS M，RUTTEN I J G，NELEMANS P J，et al. What is
18
Does F⁃FDG PET/CT change the surgical management the most accurate whole⁃body imaging modality for assess⁃
of potentially resectable colorectal liver metastases?［J］. ment of local and distant recurrent disease in colorectal
Scand J Surg，2022，111：14574969221083144 cancer? A meta⁃analysis：imaging for recurrent colorectal
［12］GEORGAKOPOULOS A，PIANOU N，KELEKIS N，et al. cancer［J］. Eur J Nucl Med Mol Imaging，2011，38（8）：
18
Impact of F⁃FDG PET/CT on therapeutic decisions in pa⁃ 1560-1571
tients with colorectal cancer and liver metastases［J］. Clin ［23］WEHRLE C J，CHÁVEZ⁃VILLA M，BYRNE M，et al. Pre⁃
Imaging，2013，37（3）：536-541 transplant metabolic tumor volume predicts recurrence
［13］SERRANO P E，GU C S，MOULTON C A，et al. Positron following liver transplantation for colorectal metastasis：a
emission tomography combined with computed tomogra⁃ multicenter study［J］. Liver Transpl，2025，31（3）：298-
phy vs. no positron emission tomography combined with 310
computed tomography for the management of patients ［24］KARAO GLAN H，KEPENEK F，KÖMEK H，et al. The
with resectable colorectal cancer liver metastases and syn⁃ prognostic role of whole ⁃ body volumetric positron emis⁃
chronous extrahepatic disease［J］. Am Surg，2021，87（9）： sion tomography/computed tomography parameters in
1431-1437 treatment naive colorectal cancer patients with liver me⁃
［14］ZHOU N N，GUO X Y，SUN H W，et al. The value of tastases［J］. Nucl Med Commun，2025，46（1）：55-59
18
F⁃FDG PET/CT and abdominal PET/MRI as a one⁃ ［25］GRUT H，STERN N M，DUELAND S，et al. Preoperative
stop protocol in patients with potentially resectable 18 F⁃FDG PET/computed tomography predicts survival fol⁃
colorectal liver metastases［J］. Front Oncol，2021，11： lowing resection for colorectal liver metastases［J］. Nucl
714948 Med Commun，2020，41（9）：916-923
［15］SAMIM M，MOLENAAR I Q，SEESING M F J，et al. The ［26］NEMETH Z，WIJKER W，LENGYEL Z，et al. Metabolic
18
diagnostic performance of F⁃FDG PET/CT，CT and MRI parameters as predictors for progression free and overall
in the treatment evaluation of ablation therapy for colorec⁃ survival of patients with metastatic colorectal cancer［J］.
tal liver metastases ：a systematic review and meta ⁃ Pathol Oncol Res，2020，26（4）：2683-2691
analysis［J］. Surg Oncol，2017，26（1）：37-45 ［27］DURAN DERIJCKERE I，LEVILLAIN H，BOHLOK A，
［16］LI X F，LI M D，SHEN H，et al. Evaluation of therapeutic et al. The metabolic clinical risk score as a new prognos⁃
effect of tumor⁃targeted therapy［J］. Onco Targets Ther， tic model for surgical decision ⁃ making in patients with
2012，5：191-198 colorectal liver metastases［J］. J Surg Oncol，2020，121
［17］FINESSI M，BELLÒ M，GIUNTA F P，et al. Intervention⁃ （2）：350-356
al locoregional treatment and metabolic response：advan⁃ ［28］GRUT H，LINE P D，LABORI K J，et al. Survival after liv⁃
tages of using PET/CT in the evaluation of response to er resection and liver transplantation for colorectal liver
treatment［J］. J Nucl Med Mol Imaging，2018，62（2）： metastases：a comparative analysis stratified by metabolic
18
165-184 tumor volume assessed by F ⁃ FDG PET/CT［J］. HPB，
［18］DECAZES P，THUREAU S，MODZELEWSKI R，et al. 2022，24（7）：1055-1062
Benefits of positron emission tomography scans for the ［29］GRUT H，LINE P D，SYVERSVEEN T，et al. Metabolic